EssilorLuxottica has announced the acquisition of Ikerian AG, a Swiss health technology company, operating under the RetinAI brand, which specialises in AI and data management in eyecare.
A media release said the move reinforced the group’s “med-tech journey, adding advanced software powered by machine learning and computer vision”.
It said the software would help streamline clinical, research and pharmaceutical workflows, and deliver actionable AI-driven insights to help healthcare professionals and enhance patient care.
RetinAI develops advanced tools to collect, process and grade large-scale retinal images and biomarker datasets.
Its FDA-cleared platform, RetinAI Discovery, applies AI models to support diagnosis and monitoring of disease progression – including age-related macular degeneration (AMD), glaucoma and diabetic retinopathy – enabling more accurate and timely decisions in managing eye diseases.
EssilorLuxottica said RetinAI also partnered with pharmaceutical companies and research organisations that leverage proprietary real-world evidence to accelerate clinical studies and drug development.
“In the past year alone, we’ve made several bold moves in med-tech, all with the goal of building the most comprehensive, digitally enabled patient journey,” said Mr Francesco Milleri, chairman and CEO at EssilorLuxottica.
“RetinAI will add incredible value to an ecosystem that already includes comprehensive eyecare, advanced diagnostics, therapeutic innovation and surgical excellence.
“Leveraging its AI-powered analytics, we can turn clinical data into insights that enable faster, more accurate diagnoses and more effective disease monitoring.
“We are ushering in a new era of healthcare, and it will be transformative for patients everywhere,” he said.
Mr Carlos Ciller, chairman and CEO of RetinAI/Ikerian AG, said: “Joining EssilorLuxottica marks a defining moment in our journey. This acquisition opens an exciting new chapter for our team and technology.
“From the start, we’ve believed in the power of data and AI to transform patient care. With EssilorLuxottica’s global reach and deep commitment to innovation, we can now bring that vision to life at an entirely new scale and level of positive impact.
“Together, we’ll shape how technology drives better healthcare, sharper vision, and improved outcomes for patients.”
